Latest news with #DocMorris
Business Insider
a day ago
- Business
- Business Insider
DocMorris (DOCM) Receives a Hold from ZKB
DocMorris (DOCM – Research Report) received a Hold rating and price target from ZKB analyst today. The company's shares closed today at CHF7.61. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Currently, the analyst consensus on DocMorris is a Moderate Buy with an average price target of CHF18.20. Based on DocMorris' latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of CHF520.76 million and a GAAP net loss of CHF59.32 million. In comparison, last year the company earned a revenue of CHF506.51 million and had a GAAP net loss of CHF59.33 million
Yahoo
16-03-2025
- Business
- Yahoo
DocMorris AG (VTX:DOCM) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
It's been a sad week for DocMorris AG (VTX:DOCM), who've watched their investment drop 19% to CHF16.60 in the week since the company reported its yearly result. The statutory results were mixed overall, with revenues of CHF1.0b in line with analyst forecasts, but losses of CHF8.25 per share, some 9.0% larger than the analysts were predicting. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year. View our latest analysis for DocMorris Taking into account the latest results, the consensus forecast from DocMorris' ten analysts is for revenues of CHF1.21b in 2025. This reflects a decent 19% improvement in revenue compared to the last 12 months. Losses are expected to be contained, narrowing 20% from last year to CHF6.62. Before this earnings announcement, the analysts had been modelling revenues of CHF1.22b and losses of CHF6.27 per share in 2025. Overall it looks as though the analysts were a bit mixed on the latest consensus updates. Although revenue forecasts held steady, the consensus also made a pronounced increase to its losses per share forecasts. The consensus price target held steady at CHF35.60, seemingly implying that the higher forecast losses are not expected to have a long term impact on the company's valuation. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on DocMorris, with the most bullish analyst valuing it at CHF60.00 and the most bearish at CHF20.00 per share. So we wouldn't be assigning too much credibility to analyst price targets in this case, because there are clearly some widely different views on what kind of performance this business can generate. As a result it might not be a great idea to make decisions based on the consensus price target, which is after all just an average of this wide range of estimates. Of course, another way to look at these forecasts is to place them into context against the industry itself. For example, we noticed that DocMorris' rate of growth is expected to accelerate meaningfully, with revenues forecast to exhibit 19% growth to the end of 2025 on an annualised basis. That is well above its historical decline of 11% a year over the past five years. Compare this against analyst estimates for the broader industry, which suggest that (in aggregate) industry revenues are expected to grow 5.0% annually. So it looks like DocMorris is expected to grow faster than its competitors, at least for a while. The most important thing to note is the forecast of increased losses next year, suggesting all may not be well at DocMorris. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates. With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for DocMorris going out to 2027, and you can see them free on our platform here.. You should always think about risks though. Case in point, we've spotted 2 warning signs for DocMorris you should be aware of, and 1 of them is concerning. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
14-03-2025
- Business
- Yahoo
DocMorris Full Year 2024 Earnings: EPS Misses Expectations
Revenue: CHF1.03b (up 6.5% from FY 2023). Net loss: CHF97.3m (loss narrowed by 17% from FY 2023). CHF8.25 loss per share (improved from CHF10.07 loss in FY 2023). All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 9.0%. Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 4.9% growth forecast for the Consumer Retailing industry in Europe. Performance of the market in Switzerland. The company's shares are down 26% from a week ago. It's necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with DocMorris (at least 1 which doesn't sit too well with us), and understanding them should be part of your investment process. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
